Skip to main content
PsyBio Therapeutics Corp. logo

PsyBio Therapeutics Corp. — Investor Relations & Filings

Ticker · PSYBF ISIN · CA74464R1000 LEI · 549300KO32JSWBZIZP18 TSXV Manufacturing
Open in API
Filings indexed 119 across all filing types
Latest filing 2022-12-01 Capital/Financing Update
Country CA Canada
Listing TSXV PSYBF

About PsyBio Therapeutics Corp.

www.psybiolife.com

PsyBio Therapeutics Corp. is an intellectual property-driven biotechnology company focused on the discovery, design, and development of psycho-targeted therapeutics for mental and neurological conditions, including CNS disorders. The company develops a portfolio of novel psychoactive compounds and their analogues. A key differentiator is its proprietary platform utilizing genetically modified bacteria for the scalable, biosynthetic manufacturing of psychoactive molecules, such as tryptamines. PsyBio is actively engaged in preclinical studies and developing its own compounds, aiming to improve treatments for various psychologic and neurologic conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a non-brokered private placement financing by PsyBio Therapeutics Corp. It details the terms of the offering, including the number of units, pricing, use of proceeds, and regulatory disclaimers. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The content focuses on capital raising activities and financing terms, which aligns with updates on company fundraising and capital structure changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing, not merely an announcement of a report publication or regulatory filing.
2022-12-01 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a press release announcing PsyBio Therapeutics Corp.'s unaudited interim financial results for the three and nine months ended September 30, 2022. It references the availability of the unaudited condensed consolidated interim financial statements and management's discussion and analysis on SEDAR, indicating this is a quarterly financial update. The document contains substantive financial results and business updates, including intellectual property and clinical development milestones, which are typical contents of an Interim / Quarterly Report. The document length (8681 characters) supports it being a full report rather than a brief announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2022-11-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Consolidated Interim Financial Statements for the Nine Months Ended September 30, 2022 and 2021' and contains detailed unaudited financial statements including statements of financial position, operations and comprehensive loss, stockholders' deficiency, and cash flows. It explicitly states it is an interim report covering a period shorter than a full fiscal year (nine months). The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of substantive financial data and notes confirms it is a comprehensive interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2022-11-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CFO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer. The document does not contain actual financial data or the interim report itself, but rather a certification of those filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report (IR) itself. The document length is short (2988 characters) and it is clearly a certification letter, not the full interim report.
2022-11-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. It explicitly states it is a certification and does not contain the actual interim financial data or analysis itself. The document length is short (2991 characters) and primarily consists of an officer's attestation regarding the interim filings. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR).
2022-11-29 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis of Financial Condition and Operating Performance' for the nine months ended September 30, 2022 and 2021, prepared by management and referencing condensed consolidated interim financial statements. It contains detailed discussion of financial condition, risks, forward-looking statements, and operational factors. The presence of MD&A and reference to interim financial statements for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains substantive financial and operational analysis, not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-11-29 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.